These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18545156)

  • 1. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.
    Riddler SA; Li X; Otvos J; Post W; Palella F; Kingsley L; Visscher B; Jacobson LP; Sharrett AR;
    J Acquir Immune Defic Syndr; 2008 Jul; 48(3):281-8. PubMed ID: 18545156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection.
    Stein JH; Merwood MA; Bellehumeur JB; McBride PE; Wiebe DA; Sosman JM
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):399-405. PubMed ID: 15576636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.
    Shahmanesh M; Das S; Stolinski M; Shojaee-Moradie F; Jackson NC; Jefferson W; Cramb R; Nightingale P; Umpleby AM
    J Clin Endocrinol Metab; 2005 Feb; 90(2):755-60. PubMed ID: 15522931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
    Saumoy M; Sánchez-Quesada JL; Martínez E; Llibre JM; Ribera E; Knobel H; Gatell JM; Clotet B; Curran A; Curto J; Masó M; Ordoñez-Llanos J; Podzamczer D
    Atherosclerosis; 2012 Nov; 225(1):200-7. PubMed ID: 23017355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.
    Saumoy M; Ordóñez-Llanos J; Martínez E; Ferrer E; Domingo P; Ribera E; Negredo E; Curto J; Sánchez-Quesada JL; Di Yacovo S; González-Cordón A; Podzamczer D
    J Antimicrob Chemother; 2015 Apr; 70(4):1130-8. PubMed ID: 25538166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.
    Lampe FC; Duprez DA; Kuller LH; Tracy R; Otvos J; Stroes E; Cooper DA; Hoy J; Paton NI; Friis-Møller N; Neuhaus J; Liappis AP; Phillips AN;
    J Acquir Immune Defic Syndr; 2010 Jul; 54(3):275-84. PubMed ID: 20658749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
    Negredo E; Ribalta J; Paredes R; Ferré R; Sirera G; Ruiz L; Salazar J; Reiss P; Masana L; Clotet B
    AIDS; 2002 Jul; 16(10):1383-9. PubMed ID: 12131215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.
    Saumoy M; Tiraboschi JM; Ordoñez-Llanos J; Ribera E; Domingo P; Mallolas J; Curto J; Gatell JM; Podzamczer D
    HIV Clin Trials; 2017 Mar; 18(2):49-53. PubMed ID: 28081673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.
    Bucher HC; Richter W; Glass TR; Magenta L; Wang Q; Cavassini M; Vernazza P; Hirschel B; Weber R; Furrer H; Battegay M; Bernasconi E
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):135-42. PubMed ID: 22156913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2003 May; 168(1):107-13. PubMed ID: 12732393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.
    Purnell JQ; Zambon A; Knopp RH; Pizzuti DJ; Achari R; Leonard JM; Locke C; Brunzell JD
    AIDS; 2000 Jan; 14(1):51-7. PubMed ID: 10714567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
    Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
    Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
    HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
    Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study.
    Freedman DS; Otvos JD; Jeyarajah EJ; Shalaurova I; Cupples LA; Parise H; D'Agostino RB; Wilson PW; Schaefer EJ
    Clin Chem; 2004 Jul; 50(7):1189-200. PubMed ID: 15107310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
    van der Valk M; Kastelein JJ; Murphy RL; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato RK; Molhuizen HO; Reiss P;
    AIDS; 2001 Dec; 15(18):2407-14. PubMed ID: 11740191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.